Close Menu

Opko

Natera discussed its cancer and transplant rejection testing businesses, while Exact Sciences explained how it will benefit from its Genomic Health acquisition.

Most diagnostics companies saw increases in share prices compared to last year, resulting in a significant jump in the 360Dx Index.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

 

The test will now be considered medically reasonable and necessary for patients over 45 with moderately elevated levels of prostate-specific antigen. 

Opko logged $181.1 million in revenues from services, $26.2 million in revenue from products, and $21.5 million from licensing and intellectual property.

Medicare contractor Novitas has been considering a limited local coverage determination for the test, which calculates PSA values and determines whether a patient may need a prostate biopsy. 

Of the 29 companies in the index, 18 companies' share prices declined while the share values of 11 increased month over month.

The company priced the offering at $1.50 per share and said it will use some of the proceeds to fund research, development, and commercialization of its portfolio.

The company will use net proceeds from the offering for R&D, commercialization of its products, working capital, and other business expenses.

The development team said a protein biomarker platform they are developing may differentiate Lyme from other conditions in doctors' offices.

Pages